List view / Grid view
Brad Sorenson, CEO of Providence Therapeutics, shares the future developments and exciting potential of mRNA therapies, including improved efficacy and wider access to vaccines, and future promise for cancer treatment.
US scientists have developed new mRNA vaccines for Zika virus and HIV-1 that produce a strong mother-to-child transmission of antibodies, in rabbits.
In this ebook are articles on the future potential for mRNA therapies and combatting new variants of the SARS-CoV-2.
The Omicron variant of the SARS CoV-2 virus has previously had a number of break-through infections. However, researchers have discovered that antibodies present in previously infected patients can neutralise variants of the COVID-19 disease.
The researchers say their new discovery could be used to design better vaccines and to gain a deeper insight into autoimmune diseases and allergies.
Australian researchers have uncovered why some forms of Streptococcus A (Strep A) are associated with severe invasive infection.
The resulting compounds, which can bind to spike proteins from the original coronavirus, could serve as a starting point for developing broad-spectrum treatments for COVID-19.
Drug Target Review’s Izzy Wood spoke to Joseph Hernandez, CEO of Blue Water Vaccines, about developing transformational vaccines to address significant health challenges globally.
US scientists have designed a mathematical model that can predict COVID-19 vaccines’ effectiveness over the long term in healthy individuals and those who have cancer or suppressed immune responses.
US researchers develop a dual-action cell therapy engineered to eliminate established tumours and train the immune system to eradicate primary tumour and prevent cancer’s recurrence.
As COVID-19 continues to evolve, researchers are still on the lookout for new ways to protect against the virus. Drug Target Review brings you some of the most recent pre-clinical developments.
Despite decades without vaccine development in the respiratory syncytia virus (RSV) space, researchers are now homing in on a potential strategy to protect individuals from this disease. Here, Drug Target Review’s Ria Kakkad spoke with Dr Christy Comeaux, Medical Lead (RSV), Janssen, about the challenges associated with RSV vaccine development and her most promising…
In this article, Drug Target Review’s Izzy Wood and Ria Kakkad share some of the most ground-breaking moments from drug discovery this year.
Researchers have detected Alongshan virus (ALSV) for the first time in Switzerland in ticks.
Elevated lipoprotein(a), or Lp(a), is a major risk factor for cardiovascular disease that affects one in five people worldwide, but currently lacks approved therapies. Here, Dr Giles Campion, EVP, Head of R&D and Chief Medical Officer of Silence Therapeutics, describes the company’s approach to developing an investigational siRNA therapy designed…
